TW200833345A - Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues - Google Patents

Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues

Info

Publication number
TW200833345A
TW200833345A TW096139538A TW96139538A TW200833345A TW 200833345 A TW200833345 A TW 200833345A TW 096139538 A TW096139538 A TW 096139538A TW 96139538 A TW96139538 A TW 96139538A TW 200833345 A TW200833345 A TW 200833345A
Authority
TW
Taiwan
Prior art keywords
animal
tumors
vitamin
tissues
administering
Prior art date
Application number
TW096139538A
Other languages
English (en)
Inventor
John G Curd
Original Assignee
Novacea Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novacea Inc filed Critical Novacea Inc
Publication of TW200833345A publication Critical patent/TW200833345A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW096139538A 2006-11-01 2007-10-22 Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues TW200833345A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86390906P 2006-11-01 2006-11-01
US96816007P 2007-08-27 2007-08-27

Publications (1)

Publication Number Publication Date
TW200833345A true TW200833345A (en) 2008-08-16

Family

ID=39365038

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096139538A TW200833345A (en) 2006-11-01 2007-10-22 Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues

Country Status (3)

Country Link
CL (1) CL2007003162A1 (zh)
TW (1) TW200833345A (zh)
WO (1) WO2008057363A2 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110152207A1 (en) * 2009-12-23 2011-06-23 Goff Jesse P Use of vitamin d glycosides and sulfates for treatment of disease
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
EP2988752A4 (en) 2013-04-24 2017-01-18 Salk Institute for Biological Studies Vitamin d receptor/smad genomic circuit gates fibrotic response
AU2014274864B2 (en) 2013-06-05 2018-10-18 Salk Institute For Biological Studies Vitamin D receptor agonists to treat diseases involving CXCL12 activity
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
AU2021212659A1 (en) 2020-01-28 2022-08-04 Reflexion Medical, Inc. Joint optimization of radionuclide and external beam radiotherapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635532A (en) * 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
CA2326117A1 (en) * 1998-03-27 1999-10-07 Oregon Health Sciences University Vitamin d and its analogs in the treatment of tumors and other hyperproliferative disorders
CN1561218A (zh) * 2001-07-27 2005-01-05 努特里奇亚有限公司 用于预防和/或治疗败血症的肠道组合物
US20040253323A1 (en) * 2003-06-11 2004-12-16 Giles Brian C. Ionic cancer therapy and methods for using same in the treatment of tumors and metastasis
WO2006036892A2 (en) * 2004-09-24 2006-04-06 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer

Also Published As

Publication number Publication date
CL2007003162A1 (es) 2008-05-30
WO2008057363A3 (en) 2008-08-14
WO2008057363A2 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
Pascoe et al. Changes in the minimum alveolar concentration of isoflurane and some cardiopulmonary measurements during three continuous infusion rates of dexmedetomidine in dogs
Myers et al. Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation
Pavez et al. Effect of fentanyl target-controlled infusions on isoflurane minimum anaesthetic concentration and cardiovascular function in red-tailed hawks (Buteo jamaicensis)
Suh et al. Prolonged therapeutic hypothermia is more effective in attenuating brain apoptosis in a swine cardiac arrest model
TW200833345A (en) Use of vitamin D compounds and mimics thereof to enhance delivery of therapeutics and oxygen to tumors and other tissues
Sinclair et al. The impact of acepromazine on the efficacy of crystalloid, dextran or ephedrine treatment in hypotensive dogs under isoflurane anesthesia
Risberg et al. The cardiovascular status of isoflurane-anaesthetized horses with and without dexmedetomidine constant rate infusion evaluated at equivalent depths of anaesthesia
MX365007B (es) Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
JP2019123730A (ja) 除痛および麻酔の提供のためのジヒドロエトルフィン
Giannakopoulos et al. The cardiovascular effects and pharmacokinetics of intranasal tetracaine plus oxymetazoline: preliminary findings
RU2007103332A (ru) Способы лечения опосредуемых ccr2 заболеваний или нарушений
JP2014079552A (ja) フィトクロームで過酸化水素の分解を触媒するシリーズ薬物
WO2012044783A8 (en) Method of achieving a thymosin beta 4 concentration in a human patient
Rizzo et al. Radiation therapy for glioma stem cells
Yackey et al. Effect of transdermally administered fentanyl on the minimum alveolar concentration of isoflurane in cats
WO2015024420A1 (zh) 局麻药止痛延时剂
Dewachter et al. Comparison of arginine vasopressin, terlipressin, or epinephrine to correct hypotension in a model of anaphylactic shock in anesthetized brown Norway rats
CN109316474B (zh) 去铁胺在制备预防和/或治疗肿瘤药物中的应用
HK1132461A1 (en) Agent comprising g-csf for prevention and treatment of diabetic peripheral neuropathy
Jaakola et al. Intramuscular dexmedetomidine premedication—an alternative to midazolam‐fentanyl‐combination in elective hysterectomy?
MXPA05010804A (es) Torio 227 para uso en radioterapia de enfermedades del tejido blando.
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
Stadlbauer et al. An observational study of vasopressin infusion during uncontrolled haemorrhagic shock in a porcine trauma model: effects on bowel function
Nelskylä et al. The use of 100% compared to 50% oxygen during ineffective experimental cardiopulmonary resuscitation improves brain oxygenation
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.